Literature DB >> 10701692

High frequency of allelic loss in dysplastic lichenoid lesions.

L Zhang1, X Cheng, Y Li, C Poh, T Zeng, R Priddy, J Lovas, P Freedman, T Daley, M P Rosin.   

Abstract

Oral lichen planus (OLP) is a common mucosal condition that is considered premalignant by some, whereas others argue that only lichenoid lesions with epithelial dysplasia are at risk of progressing into oral carcinoma. A recent study from this laboratory used microsatellite analysis to evaluate OLP for loss of heterozygosity (LOH) at loci on three chromosomal arms (3p, 9p, and 17p) (Am J Path 1997;Vol151:Page323-Page327). Loss on these arms is a common event in oral epithelial dysplasia and has been associated with risk of progression of oral leukoplakia to cancer. The data showed that, although dysplastic epithelium demonstrated a high frequency of LOH (40% for mild dysplasia), a significantly lower frequency of LOH was noted in OLP (6%), which is even lower than that in hyperplasia (14%). Such results do not support OLP as a lesion at risk for malignant transformation. As a second step of the research, we determined LOH frequencies in 61 dysplastic lichenoid lesions (mild 35; moderate 19; severe 7) using the same microsatellite markers and compared these results with data obtained from the first study and from 13 normal mucosal specimens. Dysplastic lichenoid lesions showed a high frequency of loss (54% for lichenoid lesions with mild dysplasia), but values did not differ significantly from those observed in dysplasia of similar degree without lichenoid appearance. None of the normal mucosa demonstrated LOH. Epithelial dysplasia is a sign of malignant risk, independent of lichenoid changes. Such results suggest that pathologists should search for dysplasia carefully in lesions that otherwise qualify as OLP and that caution should be used when discounting dysplasia as being merely a reactive condition in lichenoid lesions.

Entities:  

Mesh:

Year:  2000        PMID: 10701692     DOI: 10.1038/labinvest.3780026

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  8 in total

Review 1.  Epidemiologic trends in head and neck cancer and aids in diagnosis.

Authors:  Nadarajah Vigneswaran; Michelle D Williams
Journal:  Oral Maxillofac Surg Clin North Am       Date:  2014-05       Impact factor: 2.802

2.  New hope for an oral cancer solution: together we can make a difference.

Authors:  Miriam P Rosin; Catherine F Poh; J Mark Elwood; P Michele Williams; Richard Gallagher; Calum MacAulay; Wan W Lam; Ajit Auluck; Lewei Zhang; T Gregory Hislop
Journal:  J Can Dent Assoc       Date:  2008-04       Impact factor: 1.316

3.  Basement membrane degeneration is common in lichenoid mucositis with dysplasia.

Authors:  Iris Lin; Denise M Laronde; Lewei Zhang; Miriam P Rosin; Ilena Yim; Leigha D Rock
Journal:  Can J Dent Hyg       Date:  2021-02-15

4.  Deciphering squamous cell carcinoma using multidimensional genomic approaches.

Authors:  Ewan A Gibb; Katey S S Enfield; Ivy F L Tsui; Raj Chari; Stephen Lam; Carlos E Alvarez; Wan L Lam
Journal:  J Skin Cancer       Date:  2010-12-27

Review 5.  Oral lichen planus as a preneoplastic inflammatory model.

Authors:  Eleni A Georgakopoulou; Marina D Achtari; Michael Achtaris; Periklis G Foukas; Athanassios Kotsinas
Journal:  J Biomed Biotechnol       Date:  2012-05-17

Review 6.  Oral lichenoid lesions - a review and update.

Authors:  Venkatesh Vishwanath Kamath; Krishnanand Setlur; Komali Yerlagudda
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

7.  Smoking habits among patients diagnosed with oral lichen planus.

Authors:  Meir Gorsky; Joel B Epstein; Haya Hasson-Kanfi; Eliezer Kaufman
Journal:  Tob Induc Dis       Date:  2004-06-15       Impact factor: 2.600

8.  The natural history of oral mucosal lesions with both lichenoid and epithelial dysplastic features: a systematic review.

Authors:  A Thirumal Raj; Shyam S Behura; Sachin C Sarode; Gargi S Sarode; Kamran Habib Awan; Shankargouda Patil
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.